Key clinical point: The intravenous formulation of the TNF inhibitor golimumab produced durable responses and no new safety signals through 1 year of treatment in patients with active psoriatic arthritis.
Major finding: ACR20, ACR50, and ACR70 response rates in the golimumab group were 76.8%, 58.1%, and 38.6%, respectively, while in the crossover group, they were 77.0%, 53.6%, and 33.9%, respectively.
Study details: Follow-up report on the phase 3 GO-VIBRANT study of 480 adult patients with psoriatic arthritis.
Disclosures: The authors reported disclosures with AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Horizon, Janssen, Novartis, Pfizer, Sanofi, and UCB. Several authors reported current or former employment with Janssen Research & Development and stock or stock options in Johnson & Johnson.
Husni ME et al. Arthritis Care Res. 2019 Apr 12. doi: 10.1002/acr.23905.